Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2â17-year-old children with asplenia or splenic dysfunction: A phase 3 study
Vaccine Sep 21, 2017
Szenborn L, et al. - This study examined the immunogenicity and safety of pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, GSK) in at-risk children with asplenia or splenic dysfunction. Immunogenicity, as well as well tolerability of PHiD-CV, was evident in 2Â17-year-old pediatric study participants with asplenia or splenic dysfunction.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
